ALC
Alcon Inc.
NYSE · Healthcare · Medical - Instruments & Supplies · CH
$70.50
−2.19%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.8B | 10.4B | 9.9B | 9.5B | 8.7B |
| Cost of Revenue | 4.7B | 4.7B | 4.4B | 4.2B | 4.0B |
| Gross Profit | 6.1B | 5.7B | 5.5B | 5.2B | 4.7B |
| Operating Expenses | |||||
| R&D Expense | 1.4B | 990.0M | 876.0M | 859.0M | 702.0M |
| SG&A Expense | 3.6B | 3.4B | 3.3B | 3.2B | 3.1B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 34.0M | (54.0M) | (27.0M) | 140.0M | 306.0M |
| Total Operating Expenses | 5.0B | 4.4B | 4.1B | 4.2B | 4.1B |
| Cost and Expenses | 9.7B | 9.0B | 8.5B | 8.4B | 8.0B |
| Operating Income (EBIT) | 1.1B | 1.4B | 1.4B | 1.0B | 672.0M |
| Non-Operating | |||||
| Interest Income | — | 74.0M | 81.5M | 34.0M | 16.5M |
| Interest Expense | 208.0M | 204.0M | 186.2M | 189.0M | 138.4M |
| Net Interest Income | (208.0M) | (130.0M) | (104.7M) | (155.0M) | (121.9M) |
| Other Non-Op Income/Expense | (330.5M) | (200.0M) | (157.0M) | (207.0M) | (209.0M) |
| Non-Operating Income (excl Interest) | 175.5M | 200.0M | (35.0M) | 18.0M | 55.4M |
| EBT (Pre-Tax Income) | 736.3M | 1.2B | 1.3B | 832.0M | 463.0M |
| Income Tax Expense | 97.0M | 180.0M | 238.0M | (142.0M) | 128.0M |
| Bottom Line | |||||
| Net Income | 639.3M | 980.0M | 1.0B | 974.0M | 335.0M |
| Earnings from Cont. Ops | 639.3M | 980.0M | 1.0B | 974.0M | 335.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 639.3M | 980.0M | 1.0B | 974.0M | 335.0M |
| Per Share | |||||
| Basic EPS | $1.30 | $1.99 | $2.06 | $1.98 | $0.68 |
| Diluted EPS | $1.30 | $1.98 | $2.05 | $1.96 | $0.68 |
| Revenue Per Share | $22.21 | $21.01 | $20.05 | $19.18 | $17.74 |
| Shares | |||||
| Basic Shares Outstanding | 486.7M | 494.9M | 494.4M | 493.0M | 491.4M |
| Diluted Shares Outstanding | 488.7M | 496.2M | 497.5M | 496.5M | 494.4M |
| Profitability Metrics | |||||
| EBITDA | 1.8B | 2.4B | 2.7B | 2.2B | 1.8B |
| D&A | 866.0M | 1.2B | 1.2B | 1.2B | 1.2B |
| EBIT | 891.3M | 1.2B | 1.4B | 1.0B | 616.6M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026